Zydus Lifesciences to present on ZYIL1 at International Congress of Parkinson's Disease and Movement Disorders

Ahmedabad: Zydus Lifesciences, a discovery-based, global pharmaceutical company has announced that a poster highlighting the company’s oral small molecule NLRP3 inhibitor, ZYIL1, will be presented at the upcoming International Congress of Parkinson's Disease and Movement Disorders to be held from August 27th to 31st 2023 in Copenhagen, Denmark.

Abstract Title: Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitors: a potential disease modifier in Parkinson’s disorder

Abstract Number: 1346

Abstract Category: Parkinson’s Disease: Pharmacology and Therapy

Presentation Date: Wednesday, August 30, 2023

Presentation Time: 13:00 - 15:00

Mr. Pankaj R. Patel, Chairman, Zydus Lifesciences said, “Parkinson’s is a devastating disease with patients steadily losing the control on movements leading to unintended or uncontrollable movements, such as shaking, stiffness and difficulty with balance and coordination. Zydus has embarked on a novel disease modifying approach through inhibiting NLRP3 inflammasome activation through ZYIL1, thereby decreasing α-synuclein expression and reducing neuroinflammation, which may potentially prevent neurodegeneration thereby controlling Parkinson’s Disease. This is a step forward in our ongoing endeavour to developing novel therapies and addressing unmet healthcare needs of patients.”

ZYIL1 is a novel oral small molecule NLRP3 inhibitor. Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation. ZYIL1 was found distributed in the brain & CSF of various nonclinical species including mice, rats and non-human primates. The efficacy of ZYIL1 has been established in a number of validated pre-clinical models of neuroinflammation and Parkinson’s Disease. ZYIL1, has demonstrated desirable ADME profile, with good safety margin. In Phase I studies, ZYIL1 was found to be safe and well-tolerated in human volunteers [NCT04731324, NCT04972188].

Read also: USFDA approves Zydus Lifesciences Zinc Sulfate Injection